Drug resistance in the mouse cancer clinic  by Rottenberg, Sven & Borst, Piet
DS
D
a
K
A
B
B
G
P
1
t
c
r
o
e
A
i
P
g
i
t
P
d
2
t
d
t
L
T
1
dDrug Resistance Updates 15 (2012) 81– 89
Contents lists available at SciVerse ScienceDirect
Drug  Resistance Updates
journa l h omepage: www.elsev ier .com/ locate /drup
rug  resistance  in  the  mouse  cancer  clinic
ven  Rottenberg ∗, Piet  Borst
ivision of Molecular Biology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
 r  t  i  c  l  e  i  n  f  o
eywords:
BCB1/P-glycoprotein
RCA1
reast cancer
enetic modiﬁcations
redictive markers
a  b  s  t  r  a  c  t
Drug  resistance  is  one  of the most  pressing  problems  in  treating  cancer  patients  today.  Local  and  regional
disease  can  usually  be adequately  treated,  but patients  eventually  die  from  distant  metastases  that  have
become resistant  to  all  available  chemotherapy.  Although  work  on  cultured  tumor  cell  lines  has  yielded
a  lot  of  information  on  potential  drug  resistance  mechanisms,  it has  proven  difﬁcult  to translate  these
results  to clinical  drug  resistance  in patients.  The  controversy  regarding  the  contribution  of  ABC  trans-
porters  to  drug  resistance  in patients  is  one  example.  The  study  of  genetically  engineered  mouse  models
(GEMMs),  which  closely  resemble  cancer  in human  patients,  can  help  to  bridge  this  gap. In  models  for
BRCA1-  or  BRCA2-associated  breast  cancer,  we  observed  a substantial  synergy  between  the defect  in
homology-directed  DNA  repair  and  sensitivity  to DNA-targeting  drugs.  Nevertheless,  tumors  are  not  eas-
ily  eradicated  and  eventually  drug  resistance  develops.  In this  review  we  will  discuss  the  use of  the  new
generation  mouse  models  to address  major  clinical  problems,  such  as mechanisms  of  drug  resistance,
predicting  chemotherapy  response  or characterizing  the  nature  of  residual  tumor  cells  that  escape  erad-
ication. Moreover,  we will  address  the  contribution  of  ABC  transporters  to drug resistance  in  our  model.. Introduction
Over the past 4 decades we have gained detailed knowledge of
he role of ATP-binding cassette (ABC) transporters in cellular pro-
esses. In particular the contribution of ABC transporters to drug
esistance has been the subject of many investigations. For prokary-
tic or eukaryotic cells that are confronted with xenobiotics, drug
xtrusion is one of the most effective mechanisms to escape death.
 recent example comes from a high-throughput chemical screen-
ng and genome-wide association analysis in the malaria parasite
lasmodium falciparum (Yuan et al., 2011). Mutations in only 3
enes appear to explain resistance to nearly all useful compounds,
ncluding several agents that are also used to treat cancer. Two  of
hese genes mediate drug efﬂux, one encodes the ABC transporter
fMDR1.
The contribution of mammalian ABC transporters to anti-cancer
rug resistance was initially studied in cell lines (Szakacs et al.,
006). Upregulation of transporters correlated with acquired resis-
ance, and the role of transporters in causing resistance was
irectly proven by overexpression of speciﬁc transporter genes in
ransfected cells. ABCB1/P-glycoprotein (P-gp) serves as the prime
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example. It was  the ﬁrst MDR  protein identiﬁed in a drug-selected
cell line (Juliano and Ling, 1976), and since its discovery a plethora
of investigators found ABCB1 to be overexpressed in their favorite
drug-resistant cell line. Genetic ablation of the Abcb1a and Abcb1b
genes that encode ABCB1 in mice (Schinkel et al., 1997) greatly
increased the vulnerability of animals to many compounds, sup-
porting the idea that ABCB1 protects both normal and neoplastic
cell types from xenotoxins. These include various key anti-cancer
drugs used every day in clinical oncology, such as taxanes, anthra-
cyclines and vinca alkaloids. ABCB1 also has an impact on novel
drugs such as protein kinase inhibitors (Hegedus et al., 2009) or new
drug combinations, as recently observed for lenalidomide plus tem-
sirolimus in patients with relapsing multiple myeloma (Hofmeister
et al., 2011). Several other ABC transporters have been associated
with anti-cancer drug resistance, in particular ABCG2 (Robey et al.,
2010; Szakacs et al., 2006). Together, ABC transporters cover many
classical and novel anti-cancer drugs and one would therefore
expect these versatile drug eliminators to contribute to multidrug
resistance in cancer patients.
Unfortunately, these preclinical studies on ABC transporters
have not yet resulted in much beneﬁt to medical oncologists and
their patients. Several ABCB1 inhibitors that completely reversed
resistance in vitro have yielded only marginal beneﬁts to patients
Open access under CC BY-NC-ND license.(Robey et al., 2010). Even the new generation ABCB1 inhibitor
zosuquidar, which is more potent and speciﬁc than previous
inhibitors, failed to improve the efﬁcacy of standard chemother-
apy for patients suffering from acute myeloid leukemia or breast
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ancer (Cripe et al., 2010; Ruff et al., 2009). In fact, some clinical
ncologists have completely abandoned the concept of concurrent
dministration of an ABCB1 inhibitor with chemotherapy (Libby
nd Hromas, 2010). There are several factors that may  explain these
rustrating results: tumors of patients do not express the target;
ools to detect the expression of ABC transporters are not reli-
ble; redundancy of ABC transporters; the protection of normal
issues by ABC transporters requires dose reduction of the cyto-
oxic agent, if the transporter is inhibited; use of chemotherapy
ocktails that contain drugs that are only poor substrates for the
argeted transporter; inclusion of tumors for which ATP-dependent
rug efﬂux is not a relevant mechanism of resistance; or a combina-
ion of some of these. The sobering conclusion is that we  still do not
now what drug transporters contribute to resistance in patients
otwithstanding many years of intensive preclinical research. This
s part of a broader frustration: we still do not know how tumors in
atients become resistant to most classical cytotoxic chemothera-
eutic agents.
. The toolbox to study drug resistance in mouse models
Apparently, there is a disconnect between the knowledge gained
rom drug resistant cell lines studied in the test tube and the appli-
ation of this knowledge to tumors in patients. The study of drug
esistance in mouse models that mimic  human cancer could bridge
his gap. In mouse models various tools to detect ABC transporters
n drug resistant tumors can be tested and optimized. Moreover,
reatment schedules and the efﬁcacy of inhibitors are more eas-
ly investigated in mice than in humans. Human clinical trials are
ime- and cost-intensive, and there are never enough patients to
est all treatment options. Mice can also be genetically modiﬁed,
n option not available in human patients. Genetic elimination of
BC transporter function, for instance, can provide unambiguous
vidence that the transporter causes resistance. A disadvantage of
sing mouse models to study ABC transporters is that there may  be
pecies-speciﬁc properties in the regulation of gene expression or
ubstrate handling.
Regarding the choice of animal model to study drug resistance,
any options are available. Their advantages and disadvantages
ave been reviewed previously (Michalak and Jonkers, 2011;
oliti and Pao, 2011; Rottenberg and Jonkers, 2008; Sharpless and
ePinho, 2006), and the NCI has set up a useful homepage of
vailable models (http://emice.nci.nih.gov). Classically, investiga-
ors have inserted human tumor pieces (xenografts) or human
ancer cell lines into immunodeﬁcient mice, but this provides a
oor model for studying drug resistance. Such cell lines repre-
ent selected subpopulations of human cancers that have usually
dapted to cell culture conditions for decades. Despite their advan-
ages regarding experimental reproducibility, the resulting tumors
re often a suboptimal surrogate of the original tumor they are
erived from. They also rarely become resistant to drugs, presum-
bly because even immunocompromized mice can still use their
nnate immune system to ﬁnish off the cancer cells that survive
rug treatment.
Nevertheless, sophisticated xenografts can be useful in speciﬁc
ircumstances. Wu et al. (2009) used primary human breast epithe-
ial organoids in which p53 knockdown was introduced together
ith HER2 or KRAS overexpression. These cells were grafted into
humanized’ mammary fat pads and eventually gave rise to pre-
eoplastic lesions and carcinomas that resembled those found in
atients. Moreover, the so-called “tumorgraft” models have re-
ained popularity in recent years; an approach that was already
stablished in the 1970s (Garber, 2009). Basically, fresh fragments
f human tumors are propagated in immunodeﬁcient animals,
hereby preserving tumor heterogeneity and avoiding artiﬁcial innce Updates 15 (2012) 81– 89
vitro selection and adaptation. One downside of this approach is
that for some cancer types, e.g., breast cancer, only a small fraction
of individual cancers will eventually be useful for serial grafting
(Marangoni et al., 2007). Those that do take also require several
months to be established. We  still do not understand the fac-
tors involved in this in vivo selection. However, those tumorgraft
lines that do grow appear to resemble the original tumor well
in morphology, genomic proﬁle and drug response, as shown for
breast, pancreatic and childhood cancers (Garrido-Laguna et al.,
2011; Hidalgo et al., 2011; Houghton et al., 2007; Marangoni et al.,
2007). The pediatric preclinical testing program is an instructive
example of how tumorgraft models can be exploited to provide a
useful complement to clinical trials with novel anti-cancer agents
(http://pptp.nchresearch.org).
To study ABCB1-mediated drug resistance xenograft models
are still frequently used. Patel and Tannock (2009) investigated
ABCB1-overexpressing MCF-7 cells, in addition to a mouse mam-
mary sarcoma cell line. Whereas tumor cells close to blood vessels
did show an increased uptake of doxorubicin in combination with
the ABCB1 inhibitors valspodar (PSC-833) and verapamil, an oppo-
site effect was  observed in distal tumor cells. The authors suggest
that this unexpected (and unexplained) result may contribute to
the poor clinical success of these inhibitors. Another example is
the recent study by Emmink et al. (2011) in which spheres of col-
orectal tumor specimens were xenografted to investigate the role
of ABCB1 to protect tumor-initiating cells from irinotecan. It was
found that the ABCB1 inhibitor valspodar (PSC-833) increased the
anti-tumor efﬁcacy of irinotecan, but unexpectedly by inhibiting
ABCB1 in more differentiated tumor cells, not the tumor-initiating
ones.
For most drugs tested, xenografts in mice respond better to drug
than tumors in patients. Differences in the setup of clinical trials and
mouse experiments may  explain part of this meagre congruence
(Kelland, 2004; Kerbel, 2003). In most clinical trials patients have
advanced, high-volume, metastatic disease, and they have already
been treated with standard chemotherapy. In many animal studies
a single drug-naïve microscopic or low-volume metastatic tumor
is treated only a few days (or hours) after grafting. Another compli-
cation is that most anti-cancer drugs increase the immunogenicity
of tumor cells in mice (Zitvogel et al., 2008). Once the xenograft has
been debulked by drug, residual activity of the immune system of
nude mice, e.g., NK-T cells, may  be sufﬁcient to kill off the remaining
foreign tumor cells.
For the study of drug resistance mechanisms xenograft models
have one obvious disadvantage: once genes have been identiﬁed
that might confer resistance, they cannot be modiﬁed genetically
without prior tumor dissociation, in vitro culturing and selection.
Here, genetically engineered mouse models (GEMMs) have an edge.
GEMMs  traditionally employ the introduction of germline mod-
iﬁcations that result in the targeted expression or inhibition of
selected genes in speciﬁc organs, as summarized elsewhere (Politi
and Pao, 2011; Walrath et al., 2010). In particular the develop-
ment of mouse strains with multiple gene replacements, guided by
our knowledge of human cancer genetics, resulted in conditional
GEMMs  which mimic  the stochastic tumorigenesis seen in patients
(Jonkers and Berns, 2002). Tumors that arise in these models often
resemble their human counterparts in their histopathological and
genetic features. Moreover, the development of inducible models,
in which genes within selected cells are switched on or off using a
chemical or viral trigger, has further improved GEMMs. The gener-
ation and characterization of GEMMs  requires years, however. The
increasing inﬂux of new drug target genes/networks derived from
high-throughput genomic or proteomic analyses has therefore
increased the need for non-germline methods to introduce genetic
modiﬁcations more efﬁciently (Heyer et al., 2010). These include
transplantation models in which genetically modiﬁed somatic stem
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r progenitor cells are implanted into the corresponding adult tis-
ue of a recipient mouse (Evers et al., 2010; Vafaizadeh et al., 2010;
ender et al., 2008). In case the isolation of stem or progenitor cells
s a limiting factor, chimeric mice may  be generated by modify-
ng mouse embryonic stem cells (ESCs) (Watters et al., 2009; Zhou
t al., 2010). Another promising approach is the possibility of gen-
rating chimeric mice using ES cells from already existing GEMMs
Huijbers et al., 2011). Potent and reversible inhibition of a gene
f interest can be achieved in the mouse ESCs by the introduc-
ion of shRNA constructs (Premsrirut et al., 2011; Seibler et al.,
007). Hence, GEMMs  offer a number of versatile tools that can
e exploited to study drug responses (Kim and Sharpless, in press)
nd tackle anti-cancer drug resistance.
Thus far drug resistance to classical or targeted anti-cancer
rugs has mainly been studied in GEMMs  for lymphoma, lung,
ancreatic and breast cancer (Olive et al., 2009; Pajic et al., 2009,
010; Politi and Pao, 2011; Rottenberg et al., 2008; Rottenberg
nd Jonkers, 2008; Singh et al., 2010; Watters et al., 2009; Zander
t al., 2010; Zhou et al., 2010; Zuber et al., 2009). In collabora-
ion with the group of Jos Jonkers we have employed GEMMs  for
reast cancer to elucidate mechanisms underlying drug resistance.
n these models conditional deletions of the Brca1, Brca2, or E-
adherin genes together with p53, have been introduced using the
re/loxP system (Derksen et al., 2006, 2011; Jonkers et al., 2001; Liu
t al., 2007). The stochastically developing mammary carcinomas
hat arise in these mice after several months mimic  many aspects
f the human disease. In particular, in the models for BRCA1/2-
ssociated breast cancer the deﬁciency in proper DNA damage
epair by homologous recombination (HR) is reﬂected by a high
requency of DNA copy number alterations that is comparable to
he corresponding alterations in human tumors (Holstege et al.,
010a,b). A disadvantage of the BRCA1/2 models is the absence
f macroscopically visible metastases. Nevertheless, the response
o drug of distant metastases can be studied in the other models
or invasive lobular breast cancer, in which the loss of E-cadherin
rives metastasis formation. An advantage of these models is that
umors derived from the same original tumor can be orthotopi-
ally transplanted into fully immunocompetent, syngeneic mice
Rottenberg et al., 2007). Importantly, the grafted tumors preserve
he morphology, the genomic ﬁngerprint, and the response to anti-
ancer agents of the original tumor. The orthotopic transplantation
f tumor pieces or dissociated tumor cells, without any intermedi-
te in vitro culturing step, is helpful in assessing how transplanted
umors originating from the same primary tumor respond to dif-
erent chemotherapeutics.
. Upfront lack of drug sensitivity
We have treated animals carrying Brca1−/−,p53−/−;
bcb1a/b−/−,Brca1−/−,p53−/−; Abcg2−/−,Brca1−/−,p53−/−;
rca2−/−,p53−/−; E-cadherin−/−,p53−/−; Abcb1a/b−/−,p53−/− or
53−/− mammary tumors with the maximum tolerable dose (MTD)
f the topoisomerase II inhibitor doxorubicin, the topoisomerase I
nhibitor topotecan, the taxane docetaxel or the DNA crosslinking
gent cisplatin, anti-cancer drugs that are regularly used in the
linic. We  found that Brca1−/−,p53−/− and Brca2−/−,p53−/− tumors
re highly sensitive to the DNA damage inﬂicted by doxorubicin,
opotecan, or cisplatin ((Rottenberg et al., 2007; Zander et al.,
010) and unpublished). Examples of responses to the MTD  of
oxorubicin or cisplatin are shown in Fig. 1. This sensitivity
s not unexpected given the function of BRCA1 or BRCA2 in
omology-directed DNA repair. Many tumors also responded to
he microtubule-targeting docetaxel (Rottenberg et al., 2007). In
ontrast, E-cadherin−/−,p53−/− or p53−/− mammary tumors only
howed a modest response, even tumors that grow as rapidly asnce Updates 15 (2012) 81– 89 83
the BRCA1/2-deﬁcient tumors (unpublished observation). Hence,
fast proliferation is not sufﬁcient to make tumor cells susceptible
to chemotherapy.
In contrast, defects in DNA repair have an enormous impact. This
is illustrated by the success of the poly(ADP-ribose)-polymerase
(PARP) inhibitor olaparib (AZD2281). PARP inhibition prevents
repair of single strand DNA breaks, which are eventually con-
verted into double strand breaks during DNA replication. Whereas
homologous recombination-proﬁcient cells are capable of repair-
ing these breaks in an error-free manner, PARP inhibition induces
synthetic lethality in BRCA1- or BRCA2-deﬁcient cells (Bryant
et al., 2005; Farmer et al., 2005). In line with this hypothesis, we
observed in our BRCA models a high olaparib sensitivity whereas
E-cadherin−/−,p53−/− or p53−/− mammary tumors did not respond
(Evers et al., 2008; Rottenberg et al., 2008). This olaparib sensitiv-
ity was  also observed in other BRCA1/2 mouse models (Hay et al.,
2009; Kortmann et al., 2011) and in human patients (Audeh et al.,
2010; Fong et al., 2009, 2010; Tutt et al., 2010).
These results show that tumors do respond to chemotherapy
if the tumor contains a well-deﬁned tumor-speciﬁc target (i.e. a
defect in DNA repair), if the drug speciﬁcally exploits this target,
and if the drug reaches the target at sufﬁcient concentrations. So
why is there so much primary chemotherapy resistance in patients?
The obvious answer is that we are still fairly ignorant. For most of
the classical cytotoxic drugs, we still do not know exactly why they
(sometimes) kill tumor cells more effectively than normal cells and
why this killing does not occur or not sufﬁciently occur in real life.
This is where GEMMs  can help to collect essential information.
Obviously, the drug needs to reach its target to act, and this does
not always happen, as shown for gemcitabine by Olive et al. (2009)
using a GEMM for pancreatic cancer. In that GEMM drug deliv-
ery can be achieved by inhibiting the hedgehog signaling pathway.
Even then the responses of the KRAS- and p53-mutated tumors
are not impressive. A KRAS-driven GEMM for lung adenocarcino-
mas  also barely responds to cisplatin (Oliver et al., 2010). Only by
targeting translesion synthesis-mediated DNA repair, tumors were
sensitized (Doles et al., 2010). These ﬁndings underline the urgent
need to ﬁnd new therapeutic approaches for tumors that are driven
by oncogenic KRAS.
Based on the preclinical work, the identiﬁcation of patients that
carry tumors with a dysfunctional DNA damage response, such as
HR deﬁciency (HRD), seems logical. At present, it is still unclear
to what extend human tumors contain other HR deﬁciencies than
BRCA1/2 mutations. A recent integration of genomic and epige-
nomic data suggested that about half of the high-grade serous
ovarian carcinomas are defective in HR (Cancer Genome Atlas
Research Network, 2011). In addition, Rad51D was just identiﬁed
as another HR pathway protein mutated in some ovarian cancers
(Loveday et al., 2011). Features of BRCA dysfunction (“BRCAness”)
including mutations, promoter methylation, reduced RNA expres-
sion, typical histopathological features, or characteristic DNA copy
number alterations are also frequent in the group of patients
with hormone receptor- and HER2-negative (“triple-negative”)
breast cancer (Da Silva and Lakhani, 2010; Lips et al., 2011; Turner
et al., 2004). In estrogen receptor-positive tumors, a BRCA2-like
comparative genomic hybridization pattern and ampliﬁcation of
the EMSY gene, which encodes a BRCA2-inhibiting protein, were
commonly found (Lips et al., 2011). In line with the preclinical data,
recent studies have shown that tumors displaying features of HRD
showed increased chemotherapy sensitivity (Graeser et al., 2010;
Kriege et al., 2009; Lips et al., 2011; Silver et al., 2010; Vollebergh
et al., 2011).Nevertheless, these clinical trials also illustrate that the pres-
ence of a BRCA1/2 mutation is no guarantee for therapy success.
Several mutation carriers did not beneﬁt from olaparib or neoad-
juvant chemotherapy. Moreover, BRCA1/2-associated cancers are
84 S. Rottenberg, P. Borst / Drug Resistance Updates 15 (2012) 81– 89
Fig. 1. Responses of BRCA1;p53-deﬁcient tumors to the maximum tolerable dose of doxorubicin or cisplatin. Animals with 3 individual orthotopically transplanted
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BRCA1;p53-deﬁcient mammary tumors (T1, T2 and T3; volume ∼200 mm3) were
er  kg i.v. When tumors relapsed or showed progressive growth (tumor size ≥50%)
doxorubicin) and triangles (cisplatin).
onsidered highly aggressive, and one would not expect a poor
rognosis of a highly drug sensitive tumor. How can this paradox
e resolved? One explanation is re-activation of BRCA function.
RCA1/2 function can be restored via genetic reversion of a
mall mutation (Edwards et al., 2008; Sakai et al., 2008; Swisher
t al., 2008), but we still do not know how frequent this is
n patients. If BRCA1/2 are silenced via promoter methylation,
he genes may  be re-activated by demethylation. Ovarian cancer
atients with BRCA1/2 mutations live longer than patients with
RCA1/2 promoter methylation (65). Apparently, cells that lackntreated (control) or treated with 5 mg  doxorubicin per kg i.v., or 6 mg  cisplatin
 recovery time of 7 days, treatment was resumed as indicated by the ﬁlled squares
promoter methylation may  be selected out more easily during
chemotherapy than drug resistant cells with a mutation in the
BRCA1/2 gene.
A second explanation for the poor survival of patients with
BRCA-altered tumors comes from GEMMs  generated in the Jonkers
lab in which BRCA1 founder mutations were introduced in mice
(Drost et al., 2011). Although the C61G mutation, which affects the
BRCA1 RING domain, promotes mammary tumor formation just
as effectively as a large intragenic Brca1 deletion, tumors with the
C61G mutation respond poorly to cisplatin or olaparib treatment.
esistance Updates 15 (2012) 81– 89 85
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Fig. 2. Gene expression proﬁling of docetaxel-sensitive versus resistant
Brca1−/−;p53−/− mouse mammary tumors. (A) 20 drug-naïve tumors were
analyzed for Abcb1b gene expression by quantitative reverse transcriptase-
multiplex ligation-dependent probe ampliﬁcation (RT-MLPA, top left insert). 10 of
these tumors were docetaxel-sensitive (white bars, average of 3 experiments + SD)
whereas 10 responded only poorly to docetaxel (black bars, average of 3 experi-
ments + SD). 5 of the 10 resistant tumors contain Abcb1b RNA levels known to be
high enough to make the tumors resistant to drug. The same samples were also
analyzed by genome-wide expression proﬁling using 39K mouse exonic evidence
based oligonucleotide (MEEBO) arrays and the 2 groups were subsequently
compared by signiﬁcance analysis of microarrays (SAM, x axis = expected values;
y  axis = observed values). (B) RNA of 5 docetaxel-sensitive Brca1−/−;p53−/− mouse
mammary tumors and RNA isolated from the matching tumor which eventuallyS. Rottenberg, P. Borst / Drug R
his suggests that hypomorphic activity of the BRCA1-C61G protein
hwarts drug sensitivity.
A third explanation also comes from experiments on GEMMs.
creens in BRCA1-deﬁcent mouse ES cells identiﬁed loss of 53BP1
s a mechanism to partially re-activate HR in cells without func-
ional BRCA1 (Bouwman et al., 2010; Bunting et al., 2010). In
RCA1;p53-deﬁcient mammary tumors we found that 53BP1 loss
auses olaparib or topotecan resistance (Jaspers, Jonkers and Rot-
enberg, unpublished observation). Since 53BP1 is also often absent
n triple-negative breast cancer (Bouwman et al., 2010), this may  be
nother mechanism that corrupts the success of anti-cancer drugs.
As fourth explanation we found increased drug efﬂux. In 5 out
f 22 BRCA1/p53-deﬁcient mouse mammary tumors that did not
espond to the MTD  of docetaxel or doxorubicin, an increased
xpression of the mouse Abcb1a/b genes was observed (Rotten-
erg and Borst, unpublished observation). This is also the cause
f resistance to doxorubicin that arises during long-term treat-
ent, as illustrated in Fig. 1. Tumor-speciﬁc deletion of the Abcb1a/b
enes resulted in docetaxel hypersensitivity. In contrast, ablation of
bcb1a/b did not sensitize p53-deﬁcient tumors to docetaxel. This
trongly suggests that loss of BRCA1 function is the critical factor
hat contributes to docetaxel sensitivity.
A ﬁfth explanation is epithelial-mesenchymal transition (EMT)
Singh and Settleman, 2010). Only a small fraction of breast can-
ers in patients show a metaplastic phenotype, and these tumors
re indeed usually drug resistant (Weigelt et al., 2009). In our
RCA1/2-deﬁcient mouse mammary tumors we also found a small
raction of EMT  tumors, and these tumors poorly responded to sev-
ral anti-cancer drugs (unpublished observation). As expected, the
MT  phenotype correlated with a drastic change in the gene expres-
ion proﬁle. This also includes increased Abcb1a/b gene expression.
e  are currently investigating whether this is causal by itself, as
uggested by Li et al. (2009).
. Predicting resistance
The examples presented in the preceding section illustrate only
ome complications that can hamper the success of chemotherapy
f tumors that one may  classify as being drug sensitive. Several
dditional mechanisms can be envisioned, including lack of drug
mport, drug metabolism or drug target alterations. These exam-
les also demonstrate why it is so difﬁcult to predict chemotherapy
esponse (Borst and Wessels, 2010). Small mutations of BRCA1 or
3BP1 genes, that may  be sufﬁcient for restoration of DNA repair,
ill not be easily picked up. In addition, a moderate three-to ﬁve-
old increase of Abcb1 gene expression, which is enough to cause
omplete doxorubicin or olaparib resistance in our model (Pajic
t al., 2009; Rottenberg et al., 2008), may  not be easily detected
sing ordered arrays.
Another complication is the presence of multiple mechanisms
f drug resistance. Only if a mechanism occurs in the major-
ty of resistant tumors, conventional analysis tools of large data
ets will ﬁnd a signiﬁcant difference. This is shown in Fig. 2
or some Brca1−/−;p53−/− mouse mammary tumors. 20 individ-
al tumors that were sampled before treatment were analyzed
y gene expression proﬁling (Rottenberg and Borst, unpublished
bservation). In subsequent experiments we found that 10 tumors
here named tumor 1–10) were sensitive to docetaxel, whereas
0 other tumors (tumor 11–20) were not. Supervized signiﬁcance
nalysis of microarrays (SAM) based on the therapy outcome did
ot yield a single gene that correlated with therapy response.
n contrast, when matched samples of 5 Brca1−/−;p53−/− tumors
T21-25) before docetaxel treatment and of the docetaxel resis-
ant tumor were analyzed, Abcb1b was identiﬁed using the same
nalysis (Fig. 2B). Quantitative analysis of Abcb1b gene expressionacquired docetaxel resistance with increased Abcb1b RNA levels were analyzed as
described under (A).
showed for tumors 1–20 increased transcripts for 5 of the 10 poor
responders, whereas all 5 tumors which acquired docetaxel resis-
tance had increased Abcb1b RNA levels. Hence, even if a mechanism
can explain drug resistance in half of the samples, it may  not be
detected by classical gene expression proﬁling.
The BRCA1 deﬁciency illustrates how a speciﬁc defect in DNA
repair can sensitize tumors to chemotherapy, but the examples pro-
vided also show how easily such defects are sometimes reversed. A
functional assay by which DNA repair can be measured in patients
would therefore be useful. Such tests may  be applied and optimized
in GEMMs  under controlled conditions. One example is the mea-
surement of cell-free tumor DNA in the blood of patients (Leary
et al., 2010). Next generation sequencing provides the possibility
to identify tumor-speciﬁc DNA mutations in tumor samples. This
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nowledge allows the design of a simple PCR strategy to detect
NA in the serum of patients that is leaking from the tumor. An
ncrease in cell-free tumor DNA should reﬂect the death of many
umors cells, e.g., due to successful chemo- or radiotherapy. This
pproach may  be helpful in monitoring the success of therapy early
n. It could also be used as a quick functional readout to determine
hether a tumor has a defect in HR, using a test dose of olaparib,
hich has only few side effects.
. Drug tolerance impedes tumor eradication
Another set-back for chemotherapy is the frequent lack of
umor eradication of drug-sensitive tumors. Our experiments with
rca1−/−;p53−/− GEMM tumors using cisplatin have shed new light
n this complication (Borst et al., 2008; Pajic et al., 2010; Rottenberg
t al., 2007). Due to the large intragenic deletion, BRCA1 func-
ion cannot be restored in our model tumor (Liu et al., 2007).
oreover, cisplatin is not a substrate of P-gp, our mouse tumors
sually express 53BP1, and tumors grow rapidly. This looks like
he perfect scenario to achieve tumor eradication. Despite the high
isplatin sensitivity of this model, however, tumors are usually
ot eradicated, even not by dose-dense treatment (Pajic et al.,
010). Intriguingly, relapsing tumors are not resistant to cisplatin.
nstead, tumors that grow back from remnants always respond
gain to cisplatin and the time until relapse is not shorter after
epeated treatments (Fig. 1). Hence, the residual tumor cells that
ventually repopulate the tumor are not selected for stable drug
esistance. We  investigated whether the remnant cells may  repre-
ent tumor-initiating cells (TICs) that have increased biochemical
efense mechanism (Pajic et al., 2010). In the cisplatin-surviving
umor remnants the TICs were not enriched (Pajic et al., 2010).
his argues against the hypothesis that TICs have special biochem-
cal defense mechanisms that would make them less vulnerable to
rugs. Instead, our results are reminiscent of the drug-tolerant cells
ecently observed in vitro (Sharma et al., 2010). We  are currently
nvestigating whether cell cycle arrest of cells with tumor-initiating
apability, is underlying such drug tolerance.
Is there a role for ABC transporters in drug tolerance? When we
reated Abcg2−/−,Brca1−/−,p53−/− mammary tumors with topote-
an (Zander et al., 2010), or Abcb1a/b−/−,Brca1−/−,p53−/− with
ocetaxel, olaparib or doxorubicin (Rottenberg, Jaspers, Zander,
onkers and Borst, unpublished observation), we always found a
igniﬁcant increase in the time until tumors relapsed in comparison
o Brca1−/−,p53−/− tumors. Nevertheless, tumor eradication was
sually not achieved. This suggests that in our model drug tolerance
f drug-naïve tumors does not depend on these ABC transporters.
till, their presence helps tumors to re-grow more rapidly.
. ABC transporters frequently cause acquired drug
esistance to docetaxel, doxorubicin, topotecan, or olaparib
n Brca1−/−,p53−/− mouse mammary tumors
In contrast to our ﬁnding that relapsing tumors do not develop
isplatin resistance, Brca1−/−,p53−/− tumors always acquire resis-
ance to docetaxel, doxorubicin, topotecan or olaparib (Rottenberg
t al., 2007, 2008; Zander et al., 2010). This is exempliﬁed in
ig. 1 for doxorubicin. As underlying mechanism we frequently
ound an increased expression of the Abcb1 or Abcg2 genes.
nhibition of ABCB1 using tariquidar successfully reversed drug
esistance (Pajic et al., 2009; Rottenberg et al., 2008). The rel-
vance of ABCB1- or ABCG2-mediated drug efﬂux for acquired
rug resistance was also conﬁrmed in ABC transporter-deﬁcient
umors. Abcg2−/−,Brca1−/−,p53−/− tumors showed a delay in acquir-
ng topotecan resistance (Zander et al., 2010) and we observed
he same delay for Abcb1−/−,Brca1−/−,p53−/− tumors treated withnce Updates 15 (2012) 81– 89
olaparib (Jaspers, Jonkers and Rottenberg, unpublished obser-
vation). Even more strikingly, Abcb1−/−,Brca1−/−,p53−/− tumors
largely failed to acquire resistance to the MTD  of docetaxel or
doxorubicin (Rottenberg, Guyader, Zander and Borst, unpublished
observation). Only by lowering the dose to 50%, resistance eventu-
ally occurred (Guyader, Zander, Borst and Rottenberg, unpublished
observation). Together these data unambiguously show that in our
model increased expression of ABC transporters is a relevant mech-
anism of acquired drug resistance.
Intriguingly, we have thus far no evidence that other ABC trans-
porters than ABCB1 or ABCG2 contribute to resistance. Based on
previous studies we expected to ﬁnd topotecan or docetaxel resis-
tant tumors in which Mrp4 or Mrp7 gene expression would be
increased (Kruh et al., 2007; Leggas et al., 2004). However, in none
of the resistant tumors studied thus far, the expression of these
transporter genes was  altered.
The precise mechanisms of increased Abcb1 or Abcg2 gene
expression are still unclear. In human tumor samples and cell
lines three types of activation of the human ABCB1 gene have
been reported: DNA ampliﬁcation, DNA rearrangements linking
the ABCB1 gene to a strong promoter (Mickley et al., 1997, 1998)
and activation of a distal promoter, 100 kb upstream of the ABCB1
gene (Chen et al., 2005; Scotto, 2003). However, in our analy-
sis of the 5′-ends of the Abcb1a/b or Abcg2 mRNAs we  did not
ﬁnd either DNA ampliﬁcation, DNA rearrangements, or alterna-
tive promoter use (Pajic et al., 2009). Since the basal level of
ABCB1 in rodent tissues is higher than in most human tissues,
transcriptional activation of rodent ABCB1 may  occur more readily.
Consequently, the use of a mouse model probably results in an over-
estimation of the importance of ABC transporter-mediated drug
efﬂux as a mechanism of drug resistance in human tumors. How-
ever, the Abcb1−/−,Brca1−/−,p53−/− and Abcg2−/−,Brca1−/−,p53−/−
tumors also provide useful tools to detect ABCB1- or ABCG2-
independent drug resistance mechanisms in mice. We  have already
found that loss of 53BP1 or reduced topoisomerase I expression
explains some of the ABC transporter-independent olaparib or
topotecan resistance (Zander et al., 2010). As a tool to identify
the remaining mechanisms of resistance, we  have also derived cell
lines from several models on which we  are performing functional
screens using shRNAs or insertional mutagenesis. In tumors which
have developed resistance, we  can then validate which of the hits
identiﬁed in vitro occur in vivo.
7. Is there a future for ABC transporters in human
oncology?
Based on the results obtained thus far in breast cancer GEMMs,
we infer that ABCB1 and ABCG2 may  play a role in drug resistance
of human tumors that cannot handle the damage by efﬁcient DNA
repair. If genetic re-arrangements are required to induce human
ABCB1 or ABCG2, the frequency ABC transporter-mediated drug
resistance might well be lower than in mouse tumors in which
transcriptional activation may  be available more readily. To pro-
vide further support for the relevance of ABC transporters in human
tumors, the study of drug responses of xenografts with deﬁned
deﬁciencies in the HR pathway may  be informative. Moreover, it
would be helpful to investigate tumor samples of patients with
known DNA repair deﬁciencies that were treated with a drug
that is a substrate for ABCB1 or ABCG2. Ideally, tumor samples
of both the drug-sensitive tumor before treatment and the drug-
refractory tumor after treatment should be analyzed. Functional
in vivo imaging using (99m)Tc-sestamibi in combination with tariq-
uidar may  also be helpful in identifying those patients that may
beneﬁt from the application of an ABCB1 inhibitor in combination
with chemotherapy (Kelly et al., 2011). Given all the evidence that
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rug efﬂux is such an efﬁcient resistance mechanism for a wide
ange of prokaryotic and eukaryotic cells, human cancer cells would
e really stupid if they forgot about it.
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